DMD and Duchenne muscular dystrophy: CRISPR-Cas9-mediated genome editing has also been studied for the treatment of DMD because it can permanently replace the mutated dystrophin gene with the normal gene13,14; however, this modality faces several challenges before it can be safely translated and used clinically15.